Citable filing context
VRTX's research view summarizes recent SEC filing context, starting with earnings from Aug 3, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 3, 2026 | earnings | Vertex reported Q2 2026 revenue of $3.33 billion and raised full-year 2026 revenue guidance to $13.1-$13.2 billion. |
| Jul 7, 2026 | acquisition | Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, totaling approximately $10 billion. |
| May 13, 2026 | management_change | Shareholders elected 10 directors and approved the 2026 Stock and Option Plan at the Annual Meeting. |
| Aug 3, 2026 | Guidance: combined_gaap_rd_aiprd_sga_expenses | 6300.00 to 6450.00 |
| Aug 3, 2026 | Guidance: combined_non_gaap_rd_aiprd_sga_expenses | 5650.00 to 5750.00 |
| Aug 3, 2026 | Guidance: non_cf_product_revenue | 500.00 to not reported |
| Aug 4, 2026 | mda_quarterly | Vertex Pharmaceuticals reported strong financial growth for the first half of 2026, with total revenues reaching $6.32 billion, up 10% year-over-year. This performance was driven by its cystic fibrosis (CF) portfolio—led by TRIKAFTA/KAFTRIO and the newer ALYFTREK—alongside revenue contributions from CASGEVY (sickle cell disease and beta thalassemia) and JOURNAVX (acute pain). The company maintains a robust liquidity position, with $13.64 billion in cash, cash equivalents, and marketable securities as of June 30, 2026. To support its growth strategy, Vertex entered into a $4.5 billion term loan facility to fund the pending $10 billion acquisition of Crinetics Pharmaceuticals, expected to close in the third quarter of 2026. Key operational trends include a 31% increase in selling, general, and administrative expenses, reflecting commercial investments for JOURNAVX and the anticipated launch of povetacicept for IgA nephropathy. While the company continues to invest heavily in its pipeline, it faces ongoing legal risks, including a confidential arbitration with Royalty Pharma regarding the royalty burden on ALYFTREK. Vertex remains focused on "serial innovation," balancing internal R&D with strategic acquisitions and collaborations to diversify beyond its core CF franchise into nephrology, pain management, and cell/genetic therapies. |
| May 5, 2026 | mda_quarterly | Vertex Pharmaceuticals reported an 8% increase in total revenues to $3.0 billion for Q1 2026, driven by continued strong performance of its cystic fibrosis (CF) therapies and diversification into new disease areas. ALYFTREK revenue surged by 687% to $424.4 million, benefiting from label extensions and new reimbursement agreements in international markets, while TRIKAFTA/KAFTRIO saw a 7% decline to $2.35 billion. Non-CF products, CASGEVY for sickle cell disease and beta thalassemia, generated $42.9 million, and JOURNAVX for acute pain contributed $29.0 million, both showing significant growth following recent launches and expanded market access, including Medicare Part D coverage for JOURNAVX. Operating expenses saw a 25% increase in selling, general, and administrative costs to $493.7 million, primarily due to commercialization investments for JOURNAVX and povetacicept. Research and development expenses remained stable at $961.6 million, reflecting ongoing investment in a diversified pipeline. The company is advancing povetacicept for IgA nephropathy with a BLA submission and Priority Review Voucher, progressing inaxaplin for APOL1-mediated kidney disease towards an early 2027 interim analysis, and resuming dosing for zimislecel in Type 1 diabetes. A notable risk is the ongoing arbitration with Royalty Pharma regarding the ALYFTREK royalty rate, where Royalty Pharma claims 8% versus Vertex's 4% position. Liquidity remains strong with $13.0 billion in cash and marketable securities, and $3.0 billion remains available under the share repurchase program. |
Source: SEC EDGAR filing text and events; period Aug 3, 2026; filed Aug 3, 2026.
VRTX company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.